Gold is 2025’s best performer. UBS sees more upside
Thompson Tommy G, a director at United Therapeutics Corp (NASDAQ:UTHR), a $14.2 billion market cap biopharmaceutical company with excellent financial health and a perfect Piotroski Score of 9, recently sold 2,500 shares of the company’s common stock. The sale, executed on March 24, 2025, was carried out at an average price of approximately $318.80 per share, amounting to a total transaction value of $796,990. According to InvestingPro analysis, the stock appears undervalued at current levels.
On the same day, Thompson also acquired 2,500 shares through a stock option exercise at a price of $175.43 per share, which resulted in a total acquisition value of $438,575. Following these transactions, Thompson now directly owns 8,480 shares of United Therapeutics common stock. The company maintains impressive gross profit margins of 89% and trades at an attractive P/E ratio of 11.8.
In addition to his direct holdings, Thompson holds 8,200 shares indirectly through a trust and 5,800 shares through a family LLC. These transactions reflect Thompson’s active management of his equity in the company. For deeper insights into UTHR’s valuation and 13 additional ProTips, visit InvestingPro, where you’ll find comprehensive research reports and expert analysis.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, revealing a miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of $6.19, falling short of the anticipated $6.68, while revenue reached $735.9 million, slightly below the forecasted $739.92 million. Despite this, United Therapeutics achieved record annual revenue growth for the third consecutive year, with key products like Tyvaso and Orenitram showing strong revenue increases of 19% and 28%, respectively.
Goldman Sachs analyst Chris Shibutani adjusted the price target for United Therapeutics to $293 from the previous $302, maintaining a Neutral rating. This revision followed the company’s fourth-quarter results and was influenced by a modest reduction in Tyvaso forecasts and increased research and development spending. The early termination of the HYPERION study for Winrevair was noted, though management maintained that the long-term impact would be limited. United Therapeutics continues to advance its pipeline with significant clinical trial progress, including the anticipated first UKidney transplant around mid-2025, which is expected to attract media attention.
The outcomes of the IPF trials, TETON-2 and TETON-1, are seen as critical, with a cautious probability of success expressed by Shibutani. These developments underscore the company’s ongoing efforts to sustain growth amid competitive pressures and significant upcoming clinical trial milestones.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.